TSX Exchange Symbol: RVX
CALGARY, Feb. 1 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that the Board of Directors has elected Arthur J. Higgins, CEO of Bayer HealthCare and Chairman of the Bayer HealthCare Executive Committee, to the Board effective February 1, 2010.
Mr. Higgins joined Bayer in 2004 as Chairman of the Bayer HealthCare Executive Committee and in 2006 was named Chairman of the Board of Management of Bayer HealthCare. Mr. Higgins has played a key role in driving the success of Bayer HealthCare through a combination of strong organic growth and key acquisitions, including the (euro)17 billion acquisition of the German pharmaceutical company, Schering AG, in 2006.
"Arthur Higgins' global leadership experience and exposure to numerous healthcare markets are just a few of the reasons that he is a valued addition to the Board," said Donald J. McCaffrey, President & CEO of Resverlogix. "As we progress through our Phase 2 clinical trials, we welcome Mr. Higgins' perspective as a strategist and R&D specialist."
Mr. Higgins was born in Airdrie, Scotland. He studied at Scotland's Strathclyde University from 1974 to 1978, where he gained a Bachelor of Science degree in biochemistry.
Mr. Higgins started his career in 1978 in England with Bristol-Myers. He subsequently worked for Sandoz (1979 to 1984) and Fisons (1984 to 1987) before moving to Abbott Laboratories in the USA (1987 to 2001), where he held various positions of increasing responsibility in the international and domestic divisions, including a tw
|SOURCE Resverlogix Corp.|
Copyright©2010 PR Newswire.
All rights reserved